First Hospital Nationwide Now Offers Less-Invasive Procedure for Select Patients with Obstructed Neck Arteries
Share:
Ochsner Health System in New Orleans Conducts First Carotid Procedure with Newly-Approved Stent System
NEW ORLEANS, Oct. 9 -- The Ochsner Health System in New Orleans, Louisiana, conducted the first patient procedure involving the new, FDA-approved PRECISE® Nitinol Stent and ANGIOGUARD® Emboli Capture Guidewire carotid system. The new devices, marketed by Cordis Endovascular, a division of Cordis Corporation, are used to treat clogged neck arteries, known as carotid artery disease.
Carotid artery disease-the buildup of plaque in the major arteries of the neck that carry blood to the brain-is an important risk factor for stroke, the nation's third leading cause of death and a leading cause of serious, long- term disability. The American Heart Association estimates that 20 to 30 percent of strokes are associated with carotid artery disease, caused by particles of atherosclerotic plaque traveling into the vessels that supply the brain with oxygen and vital nutrients. Stroke affects an estimated 700,000 Americans each year.
Stephen R. Ramee MD, FACC, Section Head, Interventional Cardiology Director, Cardiac Catheterization Laboratory, Ochsner Health System, said, "More and more practitioners prefer carotid stenting over endarterectomy in appropriate cases based on the clinical evidence and safety profile. The Cordis carotid system is easy to prepare and use, has an excellent safety profile and good retrievability, which is important in order to protect the patient's brain from embolic material. Our first case was technically challenging because the patient had difficult bends in the artery and calcium in the lesion. The Cordis carotid system handled and deployed perfectly, crossed the lesion quite well and retrieved the embolic protection device flawlessly with visible debris." Christopher J. White, MD, FACC, FAHA Chairman, Department of Cardiology, Director, Ochsner Heart & Vascular Institute played a key role in the successful patient outcome of the carotid procedure. Dr. White is a world-renowned expert in carotid intervention and peripheral arterial disease.
The PRECISE® Nitinol Stent is a small, wire-mesh tube that props open the blocked artery and the ANGIOGUARD® Emboli Capture Guidewire System is a tiny, basket-like device designed to trap any particles of plaque, blood clot, or other material that may be dislodged during stent placement. The stent and protective basket are delivered by a thin plastic tube, called a catheter, inserted through a small puncture in the groin and advanced up through the major arteries in the body to the site of blockage in the neck. Once the stent is in place, the basket device is collapsed and withdrawn along with the catheter. The stent remains as a permanent implant, providing support in the carotid artery.
Cordis Endovascular
Cordis Endovascular is a recognized leader in endovascular research and development and is committed to serving the cardiology, radiology and vascular surgery communities through the development of groundbreaking technologies for the treatment of peripheral vascular disease. It constantly seeks solutions to the human anatomy's most challenging problems, such as carotid artery disease, superficial femoral artery disease, venous thrombotic disease, lower extremity disease and aortic aneurysm.
Cordis Corporation
Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in developing and manufacturing interventional vascular technology. Through the company's innovation, research and development, physicians worldwide are better able to treat the millions of patients who suffer from vascular disease.
Source: Cordis Corporation
CONTACT:
Carol Goodrich
Cordis Corporation
Office: +1-908-412-7332, Mobile: +1-973-615-4057
CGood2@crdus.jnj.com
Web site: http://www.cordis.com/
